Vaccine Info

Afluria Quadrivalent Influenza Vaccine

Authored by
Staff
Last reviewed
June 7, 2021
Fact checked by
Robert Carlson, MD
Share

Afluria Quadrivalent Influenza Vaccine Description

Afluria Quadrivalent is an inactivated egg-based influenza vaccine designed to protect against four different flu viruses, including two influenza A viruses and two influenza B viruses.

For 2021-2022, quadrivalent (four-component) egg-based vaccines are recommended to contain:

an A/Victoria/2570/2019 (H1N1)pdm09-like virus

an A/Cambodia/e0826360/2020 (H3N2)-like virus

a B/Washington/02/2019 (B/Victoria lineage)-like virus

a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus

Afluria Quadrivalent Influenza Vaccine Indication

Afluria Quadrivalent is indicated in people 6 months of age and older for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.

Afluria Quadrivalent Influenza Vaccine Dosage

Afluria is administered as an intramuscular injection by needle and syringe (6 months and older) or by PharmaJet®Stratis® Needle-Free Injection System (18 through 64 years).

Afluria Quadrivalent Influenza Vaccine News

September 16, 2020 - The American Academy of Pediatrics (AAP) recommends routine influenza immunization of all children without medical contraindications, starting at 6 months of age. Influenza vaccination is an important intervention to protect vulnerable populations and reduce the burden of respiratory illnesses during the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) pandemic. The vaccine formulations available for children 6 through 35 months of age have been updated. Afluria Quadrivalent will be the only vaccine for children 6 through 35 months of age with a dosing volume of 0.25 mL.

July 30, 2020  - Seqirus Begins Shipping 2020/21 Influenza Vaccines to the U.S. Market. "We are collaborating with our partners across the industry to ensure a reliable supply of influenza vaccines throughout the season to help ensure as many eligible people as possible get an influenza vaccination," said Dave Ross, Vice President, North America Commercial Operations at Seqirus. 

Afluria Quadrivalent Influenza Vaccine Clinical Trials

Afluria Quadrivalent has been involved in 12 studies.